MX2024007288A - Metodos de uso de un anticuerpo anti protofibrilla beta amiloide y anticuerpo anti tau. - Google Patents

Metodos de uso de un anticuerpo anti protofibrilla beta amiloide y anticuerpo anti tau.

Info

Publication number
MX2024007288A
MX2024007288A MX2024007288A MX2024007288A MX2024007288A MX 2024007288 A MX2024007288 A MX 2024007288A MX 2024007288 A MX2024007288 A MX 2024007288A MX 2024007288 A MX2024007288 A MX 2024007288A MX 2024007288 A MX2024007288 A MX 2024007288A
Authority
MX
Mexico
Prior art keywords
antibody
methods
amyloid beta
tau
beta protofibril
Prior art date
Application number
MX2024007288A
Other languages
English (en)
Spanish (es)
Inventor
Pallavi Sachdev
Larisa Reyderman
David Li
Kristin Wildsmith
Eric Mcdade
Shobha Dhadda
Lynn Kramer
Randall Bateman
Ishani Landry
Chad Swanson
Michio KANEKIYO
Michael Irizarry
June Kaplow
David Verbel
Seiichi Hayato
Robert Gordon
Sumit Rawal
Jin Zhou
Pau Aceves Baldo
Akihiko Koyama
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2021/000937 external-priority patent/WO2023111618A1/en
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2024007288A publication Critical patent/MX2024007288A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nuclear Medicine (AREA)
MX2024007288A 2021-12-17 2022-11-08 Metodos de uso de un anticuerpo anti protofibrilla beta amiloide y anticuerpo anti tau. MX2024007288A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163291315P 2021-12-17 2021-12-17
PCT/IB2021/000937 WO2023111618A1 (en) 2021-12-17 2021-12-17 Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
PCT/US2022/079509 WO2023114586A1 (en) 2021-12-17 2022-11-08 Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody

Publications (1)

Publication Number Publication Date
MX2024007288A true MX2024007288A (es) 2024-06-28

Family

ID=84387973

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024007288A MX2024007288A (es) 2021-12-17 2022-11-08 Metodos de uso de un anticuerpo anti protofibrilla beta amiloide y anticuerpo anti tau.

Country Status (8)

Country Link
US (1) US20250051427A1 (https=)
EP (1) EP4448005A1 (https=)
JP (1) JP2024547001A (https=)
KR (1) KR20240115910A (https=)
AU (1) AU2022410770A1 (https=)
CA (1) CA3242280A1 (https=)
MX (1) MX2024007288A (https=)
WO (1) WO2023114586A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025019457A1 (en) 2023-07-15 2025-01-23 Eisai R&D Management Co., Ltd. Antimicrobial peptides
WO2025049938A1 (en) * 2023-08-31 2025-03-06 Florida Atlantic University Board Of Trustees Non-invasive delivery method of antibodies to the brain for treatment of brain diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
AU2018352308B2 (en) 2017-10-16 2025-06-05 Eisai R&D Management Co., Ltd. Anti-tau antibodies and uses thereof
US20210324056A1 (en) * 2018-07-24 2021-10-21 Eisai R&D Management Co., Ltd. Methods of treatment and prevention of alzheimer's disease
CN112187401B (zh) 2019-07-03 2022-06-14 华为技术有限公司 多时间单元传输方法及相关装置
US11877315B2 (en) 2020-09-15 2024-01-16 Qualcomm Incorporated Wireless device digital beamforming capability indication

Also Published As

Publication number Publication date
KR20240115910A (ko) 2024-07-26
EP4448005A1 (en) 2024-10-23
WO2023114586A1 (en) 2023-06-22
AU2022410770A1 (en) 2024-06-13
CA3242280A1 (en) 2023-06-22
JP2024547001A (ja) 2024-12-26
US20250051427A1 (en) 2025-02-13

Similar Documents

Publication Publication Date Title
DOP2021000199A (es) ANTICUERPOS CONTRA AMILOIDE-ß CON PIROGLUTAMATO Y USOS DE ESTOS
MX2024007288A (es) Metodos de uso de un anticuerpo anti protofibrilla beta amiloide y anticuerpo anti tau.
BR112021023024A2 (pt) Anticorpo contra claudina 18a2 e uso do mesmo
NI201900086A (es) Anticuerpos humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usándolo.
BR112023016580A2 (pt) Anticorpos anti-tcr delta variáveis 1
BR112018069976A2 (pt) anticorpo multiespecífico isolado ou um fragmento de ligação ao antígeno do mesmo, composição farmacêutica, kit, e, método para tratamento de um indivíduo.
CO2024013569A2 (es) Moléculas de unión contra frα
BR112021016398A2 (pt) Anticorpos cd33 e métodos de uso dos mesmos para tratar o câncer
ECSP23003930A (es) Anticuerpos de alta afinidad dirigidos a tau fosforilados en la serina 413
BRPI0416141B8 (pt) anticorpo anti-cd52 modificado, composição farmacêutica, vetores de expressão, e método para preparar uma imunoglobulina
BR112022001336A8 (pt) Anticorpo biespecífico anti-her2/anti-4-1bb e uso do mesmo
CL2022003715A1 (es) Tubulisinas y conjugados de proteinas-tubulisina
ECSP21044421A (es) Anticuerpos anti-pmel17 y conjugados de los mismos
CL2022003390A1 (es) Métodos para tratar o prevenir las infecciones de sars-cov-2 y covid-19 con anticuerpos antiglicoproteína de espiga de sars-cov-2.
CO2023000557A2 (es) Anticuerpos y métodos para tratar enfermedades asociadas a claudina
CL2021002792A1 (es) Anticuerpo monoclonal que se une específicamente a gitr
BR112023020622A2 (pt) Anticorpo anti-masp2, fragmento de ligação ao antígeno do mesmo e uso médico do mesmo
UY39324A (es) Anticuerpos anti-betacelulina, sus fragmentos, moléculas de unión multiespecíficas, casetes de expresión, composiciones y métodos de tratamiento.
BR112022026533A2 (pt) Anticorpo anti-fxi/fxia, fragmento de ligação do mesmo, e antígenos e uso farmacêutico do mesmo
MX2022012913A (es) Anticuerpo anti-ox40 y usos del mismo.
CL2023003047A1 (es) Anticuerpo anti componente del complemento 1s (c1s)
BR112022001395A2 (pt) Métodos para administrar anticorpos anti-siglec-8 e corticosteroides
CL2025001214A1 (es) Conjugados de anticuerpo anti-cd7-fármaco y métodos de uso de los mismos
BR112023023558A2 (pt) Anticorpos anti-tmprss6 e usos dos mesmos
BR112023002234A2 (pt) Anticorpos sars-cov-2 para tratamento e prevenção de covid-19